Apimeds Pharmaceuticals US (APUS) Total Liabilities (2023 - 2025)

Apimeds Pharmaceuticals US has reported Total Liabilities for 3 years, with the latest figure at $10.8 million in Q4 2025.

• For the quarter ending Q4 2025, Total Liabilities rose 690.26% year-over-year to $10.8 million; the trailing twelve-month figure through Dec 2025 stood at $10.8 million (up 690.26% YoY), and the FY2025 full-year result was $10.8 million, up 690.26% from the prior year.
• Total Liabilities for Q4 2025 stood at $10.8 million, up from $1.1 million in the prior quarter.
• The five-year high for Total Liabilities was $10.8 million in Q4 2025, with the low at $264604.0 in Q1 2024.
• Historically, Total Liabilities has averaged $2.1 million across 3 years, with a median of $1.0 million in 2024.
• The largest YoY upside for Total Liabilities was 690.26% in 2025 against a maximum downside of 4.1% in 2025.
• Apimeds Pharmaceuticals US's Total Liabilities stood at $390207.0 in 2023, then surged by 251.4% to $1.4 million in 2024, then jumped by 690.26% to $10.8 million in 2025.
• The last three Total Liabilities figures came in at $10.8 million (Q4 2025), $1.1 million (Q3 2025), and $809002.0 (Q2 2025), per Business Quant data.